Please note that log in for BLAW products will be unavailable for scheduled maintenance on Sunday, February 5th from approximately 4 AM to 5 AM EST.
Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Covid-Pill Rationing Is Next Focus as U.S. Clears Merck, Pfizer

Dec. 23, 2021, 8:30 PM

The U.S. has cleared its first two Covid-19 treatment pills, and now comes another hurdle -- deciding who should get which one.

Merck & Co.’s molnupiravir was authorized Thursday by the Food and Drug Administration for use in adults at high risk of severe cases who have no other treatment option, though it is not recommended for pregnant women. Still, the U.S. will soon have 3 million courses available.

Meanwhile, Pfizer Inc.’s Paxlovid -- authorized earlier this week --showed stronger clinical trial data with President Joe Biden hailing the pill as “a promising new treatment.” It will be available ...